Alterity Therapeutics (ATH) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company and leadership overview

• CEO joined in 2017, bringing CNS drug development experience and a U.S. presence to an Australia-based team.

• Focus is on developing therapies for multiple system atrophy (MSA), a rapidly progressing, devastating neurodegenerative disease.

Disease background and unmet need

• MSA is aggressive, with average survival of 7–8 years and rapid loss of mobility; current therapies are only symptomatic and largely ineffective.

• There is a significant need for disease-modifying treatments that can slow progression and improve quality of life.

ATH434 mechanism and clinical rationale

• ATH434 is an iron chaperone that redistributes iron within cells, reducing its pathological impact without removing it from the body.

• The drug targets iron accumulation, a near-universal feature in MSA, as established by the bioMUSE natural history study.